Stevenson has a long-standing relationship with Oxford Sciences Enterprises. So when they needed to hire a CEO for their Oxford University spinout — Evox Therapeutics — they naturally gave us a call. We partnered with their scientific founders, Dr. Per Lundin, Dr. Matthew Wood, and Dr. Samir El Andaloussi, on the highly publicized placement. We also made several more key hires and began our deep immersion into Evox’s business.
As we continued strategic discussions with their CEO and board, one of their business needs was to advance their Neiman Pik Program. In order to make that happen, they needed a top-notch pharmaceutical partner. And we knew just the people.
We arranged an introduction between the teams at Evox and Takeda, another longtime client whose business goals we intimately understood. The result of that meeting was a $882 million deal. Moving forward as partners, their work will develop the technology to create ground-breaking treatments for some of the world’s rarest and deadliest diseases.
